KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer.

Masahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, Melissa L Johnson, Luis Paz-Ares, James Chih-Hsin Yang, Benjamin Besse, Weiji Su, Bo H Chao, Alexander Drilon

Future Oncol 18(28) 3133-3141

PMID35950566
PMCID-
DOI10.2217/fon-2022-0656
发表日期2022-08-11
摘要

摘要

Selpercatinib, a first-in-class, highly selective and potent central nervous system-active RET kinase inhibitor demonstrated clinically meaningful activity with manageable toxicity in pretreated and treatment-naive advanced/metastatic RET fusion-positive non-small-cell lung cancer (NSCLC). LIBRETTO-432 is a global, randomized, double-blind, phase III trial evaluating selpercatinib versus placebo in stage IB-IIIA, RET fusion-positive NSCLC, previously treated with definitive surgery or radiation; participants must have undergone available anti-cancer therapy (including chemotherapy or durvalumab) or not be suitable for it, per investigator's discretion. The primary end point is investigator-assessed event-free survival (EFS) in the primary analysis population (stage II-IIIA RET fusion-positive NSCLC). Key secondary end points include EFS in the overall population, overall survival, and time to distant disease recurrence in the central nervous system.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。